Global
Contact Us
DKSH has been recognized as a Great Place to Work® in 16 key markets, surpassing the number of certified markets in the previous year. DKSH has also been named one of the “Fortune 100 Best Companies to Work For™ Southeast Asia 2025”. These achievements reaffirm DKSH’s work environment and underscore its ongoing commitment to fostering a great corporate culture.
DKSH has announced Natale Capri as the sole Head of the Business Unit Performance Materials, building on his more than ten years of experience as Business Unit Co-Head. Thomas Sul, the former Co-Head, will transition into retirement.
DKSH has achieved another milestone in its sustainability efforts, as the Science Based Targets initiative (SBTi) has officially validated its near-term and net zero targets. This approval reflects DKSH’s commitment to its climate ambitions and reinforces its goal of achieving net-zero emissions by 2050.
DKSH has signed an agreement to acquire Biomedic Science Material Joint Stock Company (“Biomedic”), a leading distributor of equipment and reagents used in the biotechnology and diagnostic market in Vietnam. With this transaction, DKSH Technology further extends its scientific solutions business in line with the Business Unit’s strategy to solidify its position as a leading scientific solutions provider in Asia and Beyond.
DKSH announced today that it has signed an agreement to acquire Invita (NZ) Limited in New Zealand and Invita Australia Pty Limited in Australia (“Invita”). With this transaction, DKSH Performance Materials enhances its capabilities in the attractive food and beverage market, particularly in the dairy and nutritional segments, and strengthens its position as a leading life science and industrial specialties distributor in Asia Pacific.
DKSH Business Unit Healthcare Launches a three-part whitepaper series to help healthcare and life science companies explore industry trends and current market pressures to re-think commercial go-to market approaches in the Asia Pacific region. The whitepaper series demonstrates how strategic Commercial Outsourcing partnerships are evolving to deliver sustainable growth, resource agility, and improved patient access – successfully harnessing the region’s growing USD 10 billion healthcare outsourcing opportunity.
DKSH Holding Ltd. (“DKSH”) has, through its 100%-owned subsidiary DKSH Resources (Malaysia) Sdn Bhd (“DKSH Resources”), today submitted an offer to fully take over its Malaysian subsidiary DKSH Holdings (Malaysia) Berhad (“DHMB”) by taking over the remaining outstanding 25.7% of shares currently held by minority shareholders. As part of DKSH’s ongoing efforts to simplify company structures, DKSH subsequently aims to delist DHMB from the Malaysian stock exchange.
DKSH appoints Patrik Grande as new Head Business Unit Healthcare and new member of the Executive Committee. He follows Bijay Singh who will retire after eleven years at DKSH.
DKSH Hong Kong is leading sustainable healthcare logistics by launching its fleet of electric vehicle (EV) trucks for cross-border deliveries traversing the Hong Kong-Zhuhai-Macao Bridge (HKZM Bridge). This innovative step allows deliveries of pharmaceutical products to Macau with zero emissions, setting a new benchmark for eco-friendly distribution in the region and reinforcing DKSH’s dedication to innovation, environmental responsibility, and patients’ access to medication.
DKSH Business Unit Healthcare continues bringing patient centricity to life with “Patient Purpose Day 2025”. This global initiative, held for the third consecutive year across 12 markets across APAC and Switzerland, reinforces DKSH’s dedication to improving patient outcomes. This year, the program focuses on advancing equity in women’s health through meaningful community engagement and strategic partnerships.
DKSH Business Unit Performance Materials has been certified with the EcoVadis Gold Rating for its strong sustainability performance. The recognition highlights exceptional results in labor and human rights, as well as advanced ratings in environment, ethics, and sustainable procurement, demonstrating that sustainability is firmly embedded in the Business Unit’s operations.
DKSH celebrates its 160th anniversary, tracing its origins back to Japan in 1865. As the oldest foreign company with an uninterrupted presence in Japan, DKSH has contributed to the region’s economic development for over a century. This rich history, combined with the strong Swiss heritage, has shaped DKSH into the company it is today – a trusted partner for businesses seeking to grow in Asia and beyond.
DKSH and Chiesi have successfully secured approval to add a rare ophthalmic disease medication to the national reimbursement list in the key market in Asia, enabling earlier patient access to important eye disease treatment.
DKSH has expanded its consumer goods portfolio in Hong Kong and Macau, strengthening its partnerships with Suntory Wellness and Suntory Beverage & Food. This exclusive agreement leverages DKSH’s extensive distribution network, industry expertise, and services to support Suntory Beverage & Food in Macau for a simpler and more efficient route to market for growth as well as the launch in the new market for Suntory Wellness.
DKSH has been recognized as an “Industry Leader” for its sustainability performance in the 2025 ISS ESG Corporate Rating as the results have increased to B- (from C+). This improvement reflects DKSH’s continued commitment to sustainability, especially highlighting its climate strategy and participation in the Science Based Targets Initiative.
DKSH Business Unit Healthcare has reached a significant milestone in building a more sustainable healthcare supply chain by successfully tracking carbon emissions across its value chain through a collaboration with UOB FinLab’s GreenTech Accelerator and Smart Tradzt in Thailand. This achievement also marks the implementation of a reusable cold-chain packaging solution. The initiative underscores DKSH Healthcare’s ongoing commitment to environmental responsibility and its proactive approach to advancing sustainable business practices.
Core EBIT increased by 5.1% (at CER1) to CHF 169.3 million Core EBIT margin expanded by 10 basis points to 3.1% Net sales grew by 2.1% (at CER) to CHF 5.5 billion Five M&A transactions announced in H1 2025 Strong Free Cash Flow of CHF 121.6 million (cash conversion 117.5%) Confirmed outlook for 2025
DKSH has signed a strategic business partnership with life science company Bayer, to provide comprehensive services for a portion of the Bayer Pharmaceuticals business in Singapore, Malaysia, Thailand and the Philippines.
DKSH has been recognized as a Great Place to Work® in multiple key markets. This certification affirms the excellent work environment at DKSH and reflects the ongoing commitment to supporting and empowering its employees. DKSH aims to attain this certification across further markets as part of its continued focus on maintaining a high-performing corporate culture.
DKSH Hong Kong Business Unit Healthcare has signed an MOU with Guang Yao (Zhuhai Hengqin) Pharmaceuticals Import and Export Company Limited (Guang Yao (Zhuhai Hengqin) Pharmaceuticals) to enhance healthcare expansion in the Greater Bay Area. This partnership will facilitate the cross-border flow of healthcare products and pharmaceuticals while leveraging DKSH’s market expansion expertise and Guang Yao’s presence in China.
DKSH enters into a partnership with Klimate for carbon dioxide (CO2) removal solutions to further its mission of achieving net-zero operations. In line with the ongoing CO2 emissions reduction initiatives, DKSH will be procuring high-quality, verifiable CO2 removal credits from Klimate.
DKSH’s sustainability efforts have been recognized by EcoVadis with the Gold Medal, placing DKSH among the top 5% of rated companies globally. The improved score highlights DKSH’s continued dedication to sustainability and its proactive approach in advancing responsible business practices.
Shareholders approved all motions with a clear majority Reelection of the current Board members seeking another term as well as the Chairman of the Board of Directors, and appointment of a new Board member Proposal of dividend increase of 4.4% to CHF 2.35 per share accepted
DKSH has received Global ISO certifications for environmental practices (ISO 14001) as well as occupational health and safety (ISO 45001) across multiple markets. This achievement reinforces DKSH’s commitment to sustainability and safety in its supply chains, which are continuously improved. DKSH aims to extend these ISO certifications to other key markets in the future.
Net sales reached CHF 11.1 billion (4.0% at CER1) Core EBIT increased to CHF 343.1 (8.4% at CER1) Core EBIT margin expanded by >10 basis points to 3.1% (4th consecutive year) Free Cash Flow of CHF 256.5 million (cash conversion of 113.6%) Dividend proposal of CHF 2.35 per share (+4.4%)2 Mid-term roadmap confirmed
At today’s Capital Markets Day in London, DKSH outlines its mid-term roadmap based on the strategic priorities of growth, margin expansion, and accelerated M&A. The company presents updated Business Unit strategies and at the same time drives sustainability by committing to set a science based target. DKSH reconfirms its outlook for 2024.
DKSH Healthcare and Euris have launched “ConnectPlus”, a complete Customer Relationship Management (CRM) and Multi-Channel Engagement (MCE) platform set to transform healthcare distribution across APAC. This data-driven, agile solution enhances efficiency by providing a comprehensive view of healthcare professionals and optimizing omnichannel engagement strategies. From January 2025, ConnectPlus will strengthen DKSH Healthcare’s commitment to commercial excellence by boosting engagement with clients, customers, and patients across the healthcare ecosystem in Thailand.
DKSH and Kyowa Kirin celebrate a pivotal moment with the initiation of the partnership in South Korea, Taiwan, Singapore, Thailand, Malaysia, Hong Kong and Macau from the beginning of October. In close collaboration with Kyowa Kirin, DKSH will focus on providing end-to-end healthcare solutions, with an emphasis on improving patient access to healthcare.
DKSH has signed a strategic business partnership with Kyowa Kirin, a Japan-based global specialty pharmaceutical company, to provide comprehensive services for their specialty drugs in South Korea, Taiwan, Singapore, Thailand, Malaysia and Hong Kong & Macau. With DKSH’s expertise, distribution networks, and strong commercial capabilities, this partnership further enhances patient care and accessibility in the region.
Continued value creation in H1 2024 Core EBIT increased by 8.2% (at CER1) to CHF 163.6 million Core EBIT margin expanded by 10 basis points to 3.0% Net sales grew by 3.3% (at CER) to CHF 5.4 billion Consumer Goods Core EBIT margin reached mid-term target of 2.5% Strong Free Cash Flow of CHF 160.8 million (cash conversion 136.0%) Confirmed outlook for 2024 Capital Markets Day on November 18 in London
Shareholders approved all motions with a clear majority All current Board members reelected Proposal of dividend increase of 4.7% to CHF 2.25 per share accepted
Net sales reached CHF 11.1 billion (5.3% at CER1) Core EBIT grew to CHF 329.9 million (12.6% at CER1) Core EBIT margin expanded by >15 basis points to 3.0% Free Cash Flow of CHF 282.3 million (cash conversion at 137.0%) Dividend proposal of CHF 2.25 per share (+4.7%)2 Capital Markets Day planned in H2 2024
DKSH’s commitment to sustainability has been recognized with the internationally renowned EcoVadis Gold Medal for the second time. With its improved score, DKSH now ranks among the top 4% of all companies rated by EcoVadis. This recognition acknowledges its ongoing commitment to sustainability and its efforts to further pursue responsible business practices.
DKSH has converted its existing CHF 150 million revolving credit facility loan into a sustainability-linked revolving credit facility. This is the second sustainable finance instrument DKSH has entered into within this year, further strengthening its commitment to increase gender diversity in its senior leadership team positions, and become climate neutral (Scope 1+2) by 2030.
Net sales increased to CHF 5.6 billion (7.2% at CER1) Core EBIT grew double digit to CHF 162.6 million (15.5% at CER) Core EBIT margin expanded by 15 basis points to 2.9% Free Cash Flow of CHF 179.0 million and strong cash conversion of 168.2% Confirmed outlook for 2023
Following the collaboration which started in 2016, DKSH has announced its extended partnership with Procter & Gamble (P&G) in Hong Kong and Macau.
DKSH has converted its existing CHF 315 million bank loan into a sustainability-linked loan by tying the interest terms to its ambitious sustainability targets. These targets are consistent with DKSH's overall sustainability strategy to increase gender diversity in its senior leadership team and become climate neutral (Scope 1+2) by 2030.
DKSH has published its 2022 Sustainability Report, outlining its revised sustainability strategy and the progress made on environmental, social, and governance-related topics. Alongside, DKSH also publishes its first Task Force on Climate-Related Financial Disclosures (TCFD) Report.
Shareholders approved all motions with a clear majority All current Board members re-elected Gabriel Baertschi elected as new member of the Board of Directors Proposal of dividend increase of 4.9% to CHF 2.15 per share accepted
EBIT growth of 12.2% to CHF 319.2 million All Business Units improved performance Free Cash Flow of CHF 209.5 million (Cash Conversion 100.6%) Closing of ten acquisitions Dividend proposal of CHF 2.15 per share (+4.9%)3
DKSH and Nuance Pharma have entered into an agreement to bring the high-quality and innovative BentrioTM Nasal Spray to Hong Kong and Macau. This agreement is in line with DKSH Business Unit Healthcare’s strategic focus of expanding into higher value-added segments and services, such as medical devices.
DKSH’s commitment to Sustainability has been recognized with the internationally renowned EcoVadis Gold Rating. With its score DKSH ranks among the top 5% of the companies rated by EcoVadis.
EBIT increased by 16.6% to CHF 153.3 million (19.9% at CER¹) driven by all four Business Units EBIT margin expanded by 30 basis points to 2.7% Net sales grew by 2.0% to CHF 5,596.2 million (3.7% at CER¹) RONOC increased by 170 basis points to 20.4% Disciplined strategy and M&A execution (six acquisitions signed) Confirmed outlook for 2022
Today, DKSH has published its 2021 Sustainability Report, showing good progress on its environmental, social, and governance targets. DKSH reduced its total Scope 1 and 2 emissions by 40% in 2021, ahead of the 35% target until 2025. With this, DKSH has announced a new target to reduce 65% of its own greenhouse gas emissions by 2025. Also, DKSH now employs 29% females in senior leadership positions, up from 27% in 2020.
DKSH has joined the United Nations Global Compact initiative, the largest corporate responsibility initiative in the world, further strengthening its commitment to sustainability.
Shareholders approve all motions All Board members re-elected Dividend increase to CHF 2.05 per share approved
DKSH appoints Sam Oh, Chief Information Officer, as new member of the Executive Committee. At the same time, Daniel Culverhouse, currently Head Supply Chain Management, has decided to leave the company for personal reasons.
Net sales increase of 5.4%1 EBIT growth of 10.5% to CHF 284.6 million Profit after tax 39.6% higher than 20203 Free Cash Flow grows by 24.5% to CHF 261.6 million Consistent with progressive dividend policy, dividend 5.1% higher at CHF 2.05 per share4
PSPhere Lite+ is DKSH's innovative patient engagement platform and part of the company's digital transformation journey.
DKSH returns to growth with net sales reaching CHF 5.5 billion (+5.3%)¹Consistent strategy implementation results in 20.7% EBIT increase to CHF 131.5 million¹DKSH completes four value-accretive acquisitionsFree Cash Flow doubles compared to H1 2020
Despite COVID-19, DKSH reports key figures broadly stable on last year's level – at CER1Second consecutive year of EBIT growth in Fast Moving Consumer GoodsStrong Free Cash Flow of CHF 210.2 million (+34.1%)Assuming an easing of the impact of COVID-19, higher EBIT expected in 2021
By integrating specialty chemicals distributor Axieo, DKSH has gained broader market coverage and customer reach in the Asia Pacific region and now assumes a leading role in the Australian and New Zealand markets.
DKSH, the leading Market Expansion Services provider with a focus on Asia, has extended its partnership with Alexion Pharmaceuticals to market and distribute rare disease medicine SOLIRIS® (eculizumab).
The partnership between DKSH and International SOS has helped implement DKSH's Total Quarantine Solution which provides health and hygiene measures to safeguard the health and safety of supply chain staff in distribution centers across Asia.
Reach out to our Group Media Relations team for any inquiries.
Head, Investor and Media Relations & Sustainability, and Head, Finance Healthcare Own Brands
Manager, Group Media Relations
Contact us to discover new opportunities.